Outcomes from CheckMate-057 also confirmed the enhanced survival benefit with higher PD-L1 expression in advanced NSCLC patients treated with Nivolumab after the failure of chemotherapy (67). The gene discussed is CD274; the disease is non-small cell lung carcinoma.